Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital.

New investors Temasek, CR-CP Life Science Fund, Haitong Capital

Read the full 428 word article

How to gain access

Continue reading with a
two-week free trial.